<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-101263" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cancer Antigen 125</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gandhi</surname>
            <given-names>Tanmay</given-names>
          </name>
          <aff>King Edward Memorial</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Harshil</given-names>
          </name>
          <aff>Goshen Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tanmay Gandhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harshil Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-101263.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cancer antigen 125 (CA125) is an antigenic tumor marker expressed by epithelial ovarian neoplasms and cells lining various organs such as the endometrium, fallopian tubes, pleura, peritoneum, and pericardium.<xref ref-type="bibr" rid="article-101263.r1">[1]</xref><xref ref-type="bibr" rid="article-101263.r2">[2]</xref> CA125 is used as one of the serological tests in cases when an ovarian neoplasm is suspected and&#x000a0;for monitoring patients who have already been diagnosed with epithelial ovarian cancers.<xref ref-type="bibr" rid="article-101263.r2">[2]</xref><xref ref-type="bibr" rid="article-101263.r3">[3]</xref>&#x000a0;However, due to its low sensitivity, the test has limited use in diagnosing early ovarian cancer. The specificity is particularly low in premenopausal women; thus,&#x000a0;it is most useful&#x000a0;in postmenopausal women.<xref ref-type="bibr" rid="article-101263.r4">[4]</xref></p>
      </sec>
      <sec id="article-101263.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>CA125 is an epitope found on mucin 16 (MUC16), a<bold>&#x000a0;</bold>glycoprotein antigen present on the<bold>&#x000a0;</bold>cell surface.&#x000a0;This antigen is normally expressed in tissues derived from coelomic epithelia, such as the ovary, fallopian tube, peritoneum, pleura, pericardium, colon, kidney, and stomach.<xref ref-type="bibr" rid="article-101263.r2">[2]</xref><xref ref-type="bibr" rid="article-101263.r5">[5]</xref>&#x000a0;Currently, 3 antibodies can help identify&#x000a0;the CA125 antigen, and all 3 groups recognize nonoverlapping epitopes.<xref ref-type="bibr" rid="article-101263.r2">[2]</xref> The first group involves OC125-like antibodies, the second involves M11-like antibodies, and the third involves OV197-like antibodies.<xref ref-type="bibr" rid="article-101263.r3">[3]</xref><xref ref-type="bibr" rid="article-101263.r6">[6]</xref></p>
        <p>In a study carried out by Bast et al in 1983, elevated levels of serum CA125 (&#x0003e;35 U/mL) were present in 82% of patients with epithelial ovarian cancer, 28.5% of patients with non-gynecological cancers such as pancreatic, lung, breast, and colorectal, and 6% of the patients with benign diseases such as an ovarian cyst.<xref ref-type="bibr" rid="article-101263.r7">[7]</xref> Among gynecologic malignancies, elevated levels of CA125 correlate with adenocarcinoma of the endometrium and endocervix.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;CA125 also becomes elevated&#x000a0;under&#x000a0;certain physiological conditions, such as during menstruation,&#x000a0;the&#x000a0;first trimester of pregnancy, the postpartum period, fibroids, and pelvic endometriosis.<xref ref-type="bibr" rid="article-101263.r3">[3]</xref><xref ref-type="bibr" rid="article-101263.r9">[9]</xref><xref ref-type="bibr" rid="article-101263.r10">[10]</xref><xref ref-type="bibr" rid="article-101263.r11">[11]</xref></p>
      </sec>
      <sec id="article-101263.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The inherent function of CA125 membrane protein is still not completely clear. The latest studies suspect that the oligosaccharides associated with CA125 might play a role in cell-mediated immunity.<xref ref-type="bibr" rid="article-101263.r12">[12]</xref>&#x000a0;CA125 may have a role in inhibiting cytotoxic responses of the natural killer cells.<xref ref-type="bibr" rid="article-101263.r13">[13]</xref><xref ref-type="bibr" rid="article-101263.r14">[14]</xref>&#x000a0;Under physiological conditions, CA125 is expressed on the cell membrane. However, due to the presence of the cells' junctional complexes, it cannot cross into the bloodstream. Pathological states associated with the disruption of this membrane barrier lead to the antigen being shed into the blood and a consequent serological rise in the levels of CA125.<xref ref-type="bibr" rid="article-101263.r1">[1]</xref>&#x000a0;CA125 has been considered to play a role in promoting tumorigenesis and metastasis. This mechanism is&#x000a0;believed to occur&#x000a0;due to the&#x000a0;binding between CA125&#x000a0;and mesothelin, a glycoprotein expressed on the mesothelial cells of the peritoneum.<xref ref-type="bibr" rid="article-101263.r15">[15]</xref>&#x000a0;Elucidating this role of CA125 in oncogenesis has proposed a potential therapeutic avenue through the creation of monoclonal antibodies targeting CA125.<xref ref-type="bibr" rid="article-101263.r15">[15]</xref><xref ref-type="bibr" rid="article-101263.r16">[16]</xref></p>
        <p>In the case of ovaries, it appears that CA125 expresses when the ovarian epithelium undergoes metaplasia into a M&#x000fc;llerian-type endothelium or a neoplastic transformation.<xref ref-type="bibr" rid="article-101263.r1">[1]</xref><xref ref-type="bibr" rid="article-101263.r2">[2]</xref>&#x000a0;Upon their malignant transformation, the tumor cells invade and disrupt the architecture to enter the bloodstream.<xref ref-type="bibr" rid="article-101263.r17">[17]</xref>&#x000a0;In benign ovarian cysts, although the antigen may be shed into the cystic fluid, it is not present in the bloodstream.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref></p>
      </sec>
      <sec id="article-101263.s4" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>CA125 is detectable through serological-based tests or tissue-based studies of malignant ovarian or endometrial tissue specimens.<xref ref-type="bibr" rid="article-101263.r18">[18]</xref>&#x000a0;In addition, it may&#x000a0;be present in body fluids such as pleural fluid, peritoneal fluid in benign or malignant conditions, and ovarian cystic fluid.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;Serological assays on serum or plasma samples are the most commonly used quantitative analysis method for analyzing CA125 levels in the blood. To maintain the stability of the specimen, the serum must be separated from the clot and stored at &#x02212;30 &#x000b0;C&#x000a0;(long term) or 4 &#x000b0;C&#x000a0;(short term).<xref ref-type="bibr" rid="article-101263.r19">[19]</xref>&#x000a0;</p>
        <p>When the CA125 assay is used for cancer diagnosis, sampling should not be conducted immediately before or during menstruation because the physiological elevation of the CA125 levels may provide false-positive results.<xref ref-type="bibr" rid="article-101263.r9">[9]</xref><xref ref-type="bibr" rid="article-101263.r20">[20]</xref>&#x000a0;The serum samples for CA125 should not be collected within 2 weeks of surgery, as the levels may become falsely elevated secondary to tissue damage. CA125 levels have a half-life of 6 days and may require a few weeks to return to normal levels after surgery. A pre-treatment sample should be used as a reference for evaluating CA125 levels postoperatively.<xref ref-type="bibr" rid="article-101263.r21">[21]</xref></p>
      </sec>
      <sec id="article-101263.s5" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Two tests are available to&#x000a0;measure the levels of CA125. The original test is a radioimmunoassay using OC125 monoclonal antibody, which recognizes the antigenic determinants on the CA125 glycoprotein. The second-generation CA125 test uses two antibodies, OC125 and M11.<xref ref-type="bibr" rid="article-101263.r22">[22]</xref>&#x000a0;This test has shown a higher level of precision and improved sensitivity with a lower number of false-positive results.&#x000a0;However, subsequent research comparing the two tests did not indicate the superiority of one over the other.<xref ref-type="bibr" rid="article-101263.r23">[23]</xref></p>
        <p>These tests are made available by different commercial manufacturers in different versions, such as immunoradiometric assay (IRMA) and enzyme immunoassay (EIA). When using these tests to monitor patients longitudinally, the tests should preferably be from the same manufacturer and the same version, as different kits and versions can result in different absolute values and test sensitivity.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref></p>
        <p>Efforts have been made to enhance the specificity of the CA125 test by testing for CA125 glycoforms&#x000a0;more strongly associated with ovarian malignancy. For instance, the CA125-Tn ELISA-based test demonstrated almost a two-fold increase in specificity with no change in sensitivity.<xref ref-type="bibr" rid="article-101263.r24">[24]</xref>&#x000a0;Similarly, Other studies have shown an improved performance of certain CA125 glycoforms over the conventional CA125 test.<xref ref-type="bibr" rid="article-101263.r25">[25]</xref></p>
      </sec>
      <sec id="article-101263.s6" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>The original CA125 test is a homologous double-determinant assay with the same capture and tracer antibodies. The OC125 antibody&#x000a0;is adsorbed onto the solid phase (capture antibody), followed by the addition of the serum. The OC125 moieties on the CA125 antigen&#x000a0;then bind to the antibody. Finally, a second radiolabeled (IRMA) or an enzyme-labeled (EIA) antibody (tracer antibody)&#x000a0;is added, which binds to the antigen-antibody complexes.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;The second-generation CA125 test is a heterologous double-determinant assay, where the capture antibody is a monoclonal M11 antibody, and the tracer antibody is the OC125 antibody. Since the two antibodies do not have to bind to the same epitope, there is no competition for the same binding site, thus allowing for potentially higher sensitivity.<xref ref-type="bibr" rid="article-101263.r26">[26]</xref></p>
      </sec>
      <sec id="article-101263.s7" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>The original CA125 assay uses murine monoclonal OC125 antibody as both the capture and the tracer antibodies.&#x000a0;Although it should bind to the corresponding epitope on the CA125 antigen, some individuals demonstrate the presence of the human anti-mouse antibody or human anti-murine antibody.<xref ref-type="bibr" rid="article-101263.r26">[26]</xref>&#x000a0;These antibodies may interfere with the test by binding to the capture and tracer antibodies, leading to falsely elevated CA125 levels. Human anti-murine antibodies are observed in patients exposed to murine monoclonal antibodies for therapeutic or diagnostic purposes. This interference is less observable in the newer assays.<xref ref-type="bibr" rid="article-101263.r27">[27]</xref></p>
        <p>Pre-analytical errors while testing for tumor markers such as CA125 are related to simple specimen-related errors such as incorrect sample processing, an insufficient sample, and inappropriate handling. When conducting tests involving CA125, specific attention should be paid to the timing of specimen collection.<xref ref-type="bibr" rid="article-101263.r19">[19]</xref>&#x000a0;Blood collection should be avoided during menstruation, which can lead to falsely elevated levels (up to three-fold).&#x000a0;Caution is needed when interpreting elevated CA125 results in women with suspected endometriosis, pregnancy, and ascites.<xref ref-type="bibr" rid="article-101263.r28">[28]</xref><xref ref-type="bibr" rid="article-101263.r29">[29]</xref></p>
        <p>Human anti-murine antibodies are known to interfere with the test, and adding non-immune murine serum can neutralize this interference.<xref ref-type="bibr" rid="article-101263.r23">[23]</xref><xref ref-type="bibr" rid="article-101263.r26">[26]</xref>For patients undergoing monitoring with serial CA125 levels,&#x000a0;it is important&#x000a0;to use the same manufacturer and laboratory, preferably. If a different manufacturer or testing method needs to be employed, the recommendation is to carry out parallel testing by both methods to establish a new baseline for the patient.<xref ref-type="bibr" rid="article-101263.r30">[30]</xref></p>
      </sec>
      <sec id="article-101263.s8" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>In the original CA125 IRMA test, the cut-off point for the upper limit of normal was arbitrarily set at 35 U/mL.&#x000a0;This threshold was chosen because only 1% of the healthy population had CA125 levels greater than 35 U/mL. However, this was reduced to 0.2% of the healthy population when the cut-off point for the upper limit was raised to 65 U/mL.<xref ref-type="bibr" rid="article-101263.r7">[7]</xref>&#x000a0;The second-generation CA125 has shown to be more clinically reliable with greater precision in values less than 35 U/mL, leading to higher values&#x000a0;compared to the original CA125 test.<xref ref-type="bibr" rid="article-101263.r22">[22]</xref>&#x000a0;A meta-analysis comparing various studies using a CA125 threshold of greater than 35 U/mL for preoperative identification of an adnexal mass suspicious for ovarian cancer revealed an overall sensitivity and specificity of 78.7% and 77.9%, respectively.<xref ref-type="bibr" rid="article-101263.r31">[31]</xref>&#x000a0;</p>
        <p>Study results have shown that the test exhibits a higher sensitivity and specificity in&#x000a0;postmenopausal women compared to premenopausal women.<xref ref-type="bibr" rid="article-101263.r32">[32]</xref><xref ref-type="bibr" rid="article-101263.r33">[33]</xref>&#x000a0;The low sensitivity is due in part to the fact that CA125 is elevated only in half of the patients with early-stage epithelial ovarian cancer and rarely elevated in patients with mucinous carcinomas of the ovary. The low specificity, especially among premenopausal women, is due to the&#x000a0;elevation caused by&#x000a0;benign conditions such as fibroids, endometriosis, and pregnancy.<xref ref-type="bibr" rid="article-101263.r4">[4]</xref>&#x000a0;However, the test is relatively sensitive and specific among patients who have completed treatment for ovarian cancer. Patients&#x000a0;who appear to be clinically free of the tumor with elevations in CA125 (&#x0003e;35 U/mL) almost always have a tumor in second-look surgery.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-101263.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>CA125 plays a significant role as a tumor marker, particularly in the preoperative assessment of patients with an adnexal mass and suspected to have an ovarian malignancy.<xref ref-type="bibr" rid="article-101263.r31">[31]</xref>&#x000a0;Around 80% of the patients diagnosed with ovarian epithelial carcinoma show elevated CA125 levels, and levels are monitored post-treatment to assess the progression of the disease.<xref ref-type="bibr" rid="article-101263.r34">[34]</xref>&#x000a0;The use of CA125 for preoperative assessment is more valuable among postmenopausal&#x000a0;women compared to its use among premenopausal women.<xref ref-type="bibr" rid="article-101263.r4">[4]</xref>&#x000a0;Although an elevated CA125 level above 35 U/mL is utilized in assessing postmenopausal women, earlier guidelines from the American College of Obstetricians and Gynecologists had recommended using an arbitrary cutoff of 200 U/mL; this was, however, not supported by any research evidence.<xref ref-type="bibr" rid="article-101263.r35">[35]</xref></p>
        <p>Current guidelines suggest using formal risk assessment tests such as the risk of malignancy index or the risk of ovarian malignancy algorithm while assessing the need for gynecological referral in premenopausal women.<xref ref-type="bibr" rid="article-101263.r4">[4]</xref>&#x000a0;CA125 is successfully used for disease monitoring and evaluating the progression of the disease. A significant correlation exists between the disease progression and serum CA125 levels, with doubling or halving serum values considered clinically significant.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;</p>
        <p>CA125 levels also indicate the tumor status. Most patients with CA125&#x000a0;levels greater than 35 U/mL demonstrate disease recurrence on second-look surgery, and those with&#x000a0;CA125 levels less than 35 U/mL have minimal residual disease among half of the patients.<xref ref-type="bibr" rid="article-101263.r8">[8]</xref>&#x000a0;CA125 levels also act as an early predictor of outcomes where a deviation from the ideal CA125 regression curve suggests a poor outcome. Among patients who had undergone complete remission, elevation in CA125 occurred before the tumor recurrence in 75% of the patients.<xref ref-type="bibr" rid="article-101263.r2">[2]</xref>&#x000a0;However, using CA125 as a screening test for patients with ovarian cancer is not feasible. In subsequent studies evaluating the benefit of using multimodal screening combined with transvaginal ultrasound for ovarian cancer screening, no benefit in improving mortality was found.<xref ref-type="bibr" rid="article-101263.r36">[36]</xref></p>
        <p>CA125 may also have a role in monitoring response to chemotherapy. Serial measurements of CA125 are&#x000a0;found to correlate with clinical disease outcomes in 89% of 531 patients.<xref ref-type="bibr" rid="article-101263.r21">[21]</xref> There is a consensus among current guidelines to use CA125 to monitor the response to chemotherapy. The Gynecologic Cancer Intergroup defines response as a 50% reduction in CA125 concentration compared to a pretreatment sample.<xref ref-type="bibr" rid="article-101263.r37">[37]</xref><xref ref-type="bibr" rid="article-101263.r38">[38]</xref> The response should be confirmed and sustained for at least 20 days. Patients can only be diagnosed if&#x000a0;they have a CA125 concentration in a pretreatment sample that is twice the upper reference limit and taken 2 weeks before initiation of therapy. Additional samples are recommended at 2 to 4 weeks during treatment and at intervals of 2 to 3 weeks during follow-up. The same method should be used to monitor the patient throughout, and patients who receive immunotherapy (mouse antibodies) cannot be diagnosed.<xref ref-type="bibr" rid="article-101263.r39">[39]</xref>&#x000a0;The Food and Drug Administration approved the serial measurement of CA125 to aid in monitoring therapeutic response.<xref ref-type="bibr" rid="article-101263.r40">[40]</xref></p>
        <p>Preoperative and postoperative CA125 concentrations may be of prognostic significance.<xref ref-type="bibr" rid="article-101263.r41">[41]</xref> After primary surgery and chemotherapy, persistent elevations of CA125 concentrations are associated with poor prognosis. Patients with preoperative CA125 concentrations greater than 65&#x000a0;U/mL are reported to have a lower 5-year survival rate and a 6.37-fold risk of death compared to patients with CA125 levels less than 65&#x000a0;U/mL.<xref ref-type="bibr" rid="article-101263.r21">[21]</xref> The half-life of the CA125 antigen is reported to have an additional prognostic value. A half-life of less than 20 days is associated with improved survival compared to a half-life of more than 20 days.<xref ref-type="bibr" rid="article-101263.r26">[26]</xref> Normalization of CA125 levels after&#x000a0;3 cycles of combination therapy also correlates with improved survival. Importantly,&#x000a0;CA125 concentration is not elevated in 10% to 20% of patients with advanced ovarian cancer. For these patients, using radiological imaging techniques and monitoring other tumor markers&#x000a0;are necessary.<xref ref-type="bibr" rid="article-101263.r42">[42]</xref></p>
      </sec>
      <sec id="article-101263.s10" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>For non-waived tests, laboratory regulations require, at the minimum, analysis of at least&#x000a0;2 levels of control materials once every 24 hours. If necessary, laboratories can more frequently assay quality control (QC) samples to ensure accurate results. QC samples should be assayed after calibration or maintenance of an analyzer to verify the correct method performance.<xref ref-type="bibr" rid="article-101263.r43">[43]</xref>&#x000a0;To minimize QC when performing tests for which manufacturers&#x02019; recommendations are less than those required by the regulatory agency, such as once per month, the labs can develop an individualized quality control plan. This plan involves performing a risk assessment of potential sources of error in all testing phases and putting in place a QC plan to reduce the likelihood of mistakes.<xref ref-type="bibr" rid="article-101263.r44">[44]</xref>&#x000a0;Westgard multi-rules are used to evaluate the&#x000a0;QC runs. In case of a rule violation, proper corrective and preventive action should be taken before patient testing.<xref ref-type="bibr" rid="article-101263.r45">[45]</xref></p>
        <p>The laboratory must participate in the external&#x000a0;QC or proficiency testing program because it is a regulatory requirement published by the Centers for Medicare and Medicaid Services in the Clinical Laboratory Improvement Amendments regulations. This practice is helpful&#x000a0;to ensure the accuracy and reliability of the laboratory compared to other laboratories performing the same or comparable assays.<xref ref-type="bibr" rid="article-101263.r46">[46]</xref>&#x000a0;The PT plan should be included in the quality assessment plan and the laboratory's overall quality program.<xref ref-type="bibr" rid="article-101263.r47">[47]</xref></p>
        <p>The intricate tests conducted in clinical laboratories are the cornerstone of patient diagnosis and treatment. However, this crucial work does not come without risks. These facilities handle various potentially hazardous materials, from infectious agents to toxic chemicals. Strict adherence to safety protocols is essential to prevent accidental exposure or contamination, which includes proper handling, storing, and disposing of these materials to safeguard laboratory personnel, minimizing patient transmission risks, and ensuring the integrity of diagnostic tests.<xref ref-type="bibr" rid="article-101263.r48">[48]</xref></p>
        <p>Beyond material safety, meticulous equipment maintenance plays a critical role. Keeping laboratory instruments and safety devices, such as eyewash stations and fume hoods, in top condition is crucial for optimal functionality and mitigating potential hazards. Equally important are established and practiced emergency response plans. These plans enable staff to react swiftly and effectively in the event of accidents or incidents.<xref ref-type="bibr" rid="article-101263.r49">[49]</xref></p>
        <p>Continuous education and training are vital for the laboratory staff to stay abreast of evolving safety procedures and best practices. In addition, this fosters a culture of safety consciousness and accountability within the institution. Prioritizing lab safety does not just protect the workforce; it also strengthens the overall quality and trustworthiness of healthcare delivery. This comprehensive approach to safety includes employing appropriate personal protective equipment such as gloves, lab coats, and respirators, adhering to biosafety levels for specific infectious agents, following a dedicated chemical hygiene plan for safe chemical handling, and ensuring the proper segregation and disposal of biohazardous and chemical waste.<xref ref-type="bibr" rid="article-101263.r50">[50]</xref></p>
      </sec>
      <sec id="article-101263.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>CA125 serves a crucial role as a tumor marker&#x000a0;in diagnosing patients suspected of having ovarian cancer and monitoring disease progression. According to guidelines, it is an essential&#x000a0;criterion for referring patients with an adnexal mass suspicious of malignancy to a gynecological oncologist.&#x000a0;Although it has a higher specificity when used&#x000a0;in postmenopausal women, very high levels&#x000a0;in premenopausal women require referral. In addition, patient outcomes have been observed to improve&#x000a0;when treatment is provided by specialized gynecological oncologists and conducted&#x000a0;in hospitals with necessary consult services and multidisciplinary collaboration.<xref ref-type="bibr" rid="article-101263.r51">[51]</xref>&#x000a0;</p>
        <p>Interprofessional team care involves multiple disciplines, such as primary care physicians, gynecological oncologists, nurses, and pathologists. Each of them has an essential role in providing care for individuals with suspected ovarian cancer or monitoring the disease status, thus influencing disease management. Clinicopathologic meetings involving&#x000a0;discussions between pathologists and clinicians are a form of interprofessional care. Interprofessional team care has been shown to improve the accuracy of the diagnosis, achieve accurate staging and grading of the disease, and thus improve the management of the patient's disease. In addition to improving patient care, it provides a learning opportunity for the team members.<xref ref-type="bibr" rid="article-101263.r52">[52]</xref></p>
        <p>Nurses involved in the care of a patient with ovarian cancer are in a unique position to provide information and education to the patient and their family about the disease. In addition, they may be able to identify patients needing psychological support and counseling,&#x000a0;thereby improving the quality of life for their patients by coordinating referrals with nutritionists, physiotherapists, and psychologists.<xref ref-type="bibr" rid="article-101263.r53">[53]</xref> Evidence shows that patients treated under&#x000a0;interprofessional team care involving clinicians and physicians from different specialties had a significant survival advantage.<xref ref-type="bibr" rid="article-101263.r54">[54]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-101263.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=101263&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=101263">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/101263/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=101263">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-101263.s13">
        <title>References</title>
        <ref id="article-101263.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>The CA 125 tumour-associated antigen: a review of the literature.</article-title>
            <source>Hum Reprod</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">2651469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scholler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>CA125 in ovarian cancer.</article-title>
            <source>Biomark Med</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>513</fpage>
            <page-range>513-23</page-range>
            <pub-id pub-id-type="pmid">20477371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>MKY</given-names>
              </name>
              <name>
                <surname>Ngan</surname>
                <given-names>HYS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KKL</given-names>
              </name>
            </person-group>
            <article-title>Molecular Biomarkers for the Early Detection of Ovarian Cancer.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Oct</month>
            <day>10</day>
            <volume>23</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">36233339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists&#x02019; Committee on Practice Bulletins&#x02014;Gynecology</collab>
            <article-title>Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses.</article-title>
            <source>Obstet Gynecol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>e210</fpage>
            <page-range>e210-e226</page-range>
            <pub-id pub-id-type="pmid">27776072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charkhchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cybulski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gronwald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Narod</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Akbari</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>CA125 and Ovarian Cancer: A Comprehensive Review.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Dec</month>
            <day>11</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">33322519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Badgwell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Marquez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baggerly</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Skates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lokshin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>New tumor markers: CA125 and beyond.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2005</year>
            <season>Nov-Dec</season>
            <volume>15 Suppl 3</volume>
            <fpage>274</fpage>
            <page-range>274-81</page-range>
            <pub-id pub-id-type="pmid">16343244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Klug</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>St John</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jenison</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Niloff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Leavitt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zurawski</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.</article-title>
            <source>N Engl J Med</source>
            <year>1983</year>
            <month>Oct</month>
            <day>13</day>
            <volume>309</volume>
            <issue>15</issue>
            <fpage>883</fpage>
            <page-range>883-7</page-range>
            <pub-id pub-id-type="pmid">6310399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenemans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yedema</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bon</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>von Mensdorff-Pouilly</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>CA 125 in gynecological pathology--a review.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>1-2</issue>
            <fpage>115</fpage>
            <page-range>115-24</page-range>
            <pub-id pub-id-type="pmid">8365505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grover</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weideman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The effect of the menstrual cycle on serum CA 125 levels: a population study.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>1379</fpage>
            <page-range>1379-81</page-range>
            <pub-id pub-id-type="pmid">1442994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uesato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Increased serum CA 125 levels during the first trimester of pregnancy.</article-title>
            <source>Acta Obstet Gynecol Scand</source>
            <year>1986</year>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-5</page-range>
            <pub-id pub-id-type="pmid">3467532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sagawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nonogaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>160</volume>
            <issue>3</issue>
            <fpage>563</fpage>
            <page-range>563-6</page-range>
            <pub-id pub-id-type="pmid">2929674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kui Wong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sutton-Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lattanzio</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Dell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patankar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.</article-title>
            <source>J Biol Chem</source>
            <year>2003</year>
            <month>Aug</month>
            <day>01</day>
            <volume>278</volume>
            <issue>31</issue>
            <fpage>28619</fpage>
            <page-range>28619-34</page-range>
            <pub-id pub-id-type="pmid">12734200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>el Ouagari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teissi&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benoist</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Glycophorin A protects K562 cells from natural killer cell attack. Role of oligosaccharides.</article-title>
            <source>J Biol Chem</source>
            <year>1995</year>
            <month>Nov</month>
            <day>10</day>
            <volume>270</volume>
            <issue>45</issue>
            <fpage>26970</fpage>
            <page-range>26970-5</page-range>
            <pub-id pub-id-type="pmid">7592944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohnishi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ijuhin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nishiura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanakura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuzawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization.</article-title>
            <source>Cancer Res</source>
            <year>1996</year>
            <month>Jan</month>
            <day>15</day>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-8</page-range>
            <pub-id pub-id-type="pmid">8542600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.</article-title>
            <source>Biochim Biophys Acta Rev Cancer</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>1875</volume>
            <issue>2</issue>
            <fpage>188503</fpage>
            <pub-id pub-id-type="pmid">33421585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>802</fpage>
            <page-range>802-808</page-range>
            <pub-id pub-id-type="pmid">38008497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stieber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fateh-Moghadam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eiermann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hepp</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>CA-125 in gynecological malignancies.</article-title>
            <source>Eur J Cancer Clin Oncol</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>713</fpage>
            <page-range>713-7</page-range>
            <pub-id pub-id-type="pmid">2443359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in clinical practice: General principles and guidelines.</article-title>
            <source>Indian J Med Paediatr Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">20668599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ch'ng</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Liotta</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Petricoin</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Semmes</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>S&#x000f6;letormos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van der Merwe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>EP</given-names>
              </name>
              <collab>National Academy of Clinical Biochemistry</collab>
            </person-group>
            <article-title>National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.</article-title>
            <source>Clin Chem</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>e1</fpage>
            <page-range>e1-e10</page-range>
            <pub-id pub-id-type="pmid">18606634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balachandran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>An Observational Study of Factors affecting CA125 Levels in Premenopausal Women.</article-title>
            <source>Adv Biomed Res</source>
            <year>2023</year>
            <volume>12</volume>
            <fpage>235</fpage>
            <pub-id pub-id-type="pmid">38073732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rustin</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Role of tumour markers in monitoring epithelial ovarian cancer.</article-title>
            <source>Br J Cancer</source>
            <year>2000</year>
            <month>May</month>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>1535</fpage>
            <page-range>1535-8</page-range>
            <pub-id pub-id-type="pmid">10789720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenemans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Kamp</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Oehr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verstraeten</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum.</article-title>
            <source>Clin Chem</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>2509</fpage>
            <page-range>2509-13</page-range>
            <pub-id pub-id-type="pmid">8252723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eltabbakh</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Belinson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Paraiso</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Comparison between Centcor CA 125 and CA 125 II assays.</article-title>
            <source>Eur J Gynaecol Oncol</source>
            <year>1996</year>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>504</fpage>
            <page-range>504-6</page-range>
            <pub-id pub-id-type="pmid">8971528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels.</article-title>
            <source>Ann Transl Med</source>
            <year>2021</year>
            <month>May</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>788</fpage>
            <pub-id pub-id-type="pmid">34268401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salminen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nadeem</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rolfsen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>D&#x000f8;rum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laajala</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Gr&#x000e8;nman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hietanen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heinosalo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perheentupa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poutanen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolstad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carp&#x000e9;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lamminm&#x000e4;ki</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gidwani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hynninen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huhtinen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses.</article-title>
            <source>J Appl Lab Med</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-272</page-range>
            <pub-id pub-id-type="pmid">32445385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verheijen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>von Mensdorff-Pouilly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Kamp</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kenemans</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>CA 125: fundamental and clinical aspects.</article-title>
            <source>Semin Cancer Biol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-24</page-range>
            <pub-id pub-id-type="pmid">10202133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muto</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lepisto</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Van den Abbeele</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kassis</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>161</volume>
            <issue>5</issue>
            <fpage>1206</fpage>
            <page-range>1206-12</page-range>
            <pub-id pub-id-type="pmid">2686446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in the laboratory: closing the guideline-practice gap.</article-title>
            <source>Clin Biochem</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-9</page-range>
            <pub-id pub-id-type="pmid">11522270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lycke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulfenborg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malchau Lauesgaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kristjansdottir</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sundfeldt</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2021</year>
            <month>Nov</month>
            <day>25</day>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>1954</fpage>
            <page-range>1954-1962</page-range>
            <pub-id pub-id-type="pmid">34388324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mongia</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rawlins</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Performance characteristics of seven automated CA 125 assays.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>125</volume>
            <issue>6</issue>
            <fpage>921</fpage>
            <page-range>921-7</page-range>
            <pub-id pub-id-type="pmid">16690492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodge</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Covens</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elit</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Devries-Aboud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fung-Kee-Fung</surname>
                <given-names>M</given-names>
              </name>
              <collab>Gynecology Cancer Disease Site Group</collab>
            </person-group>
            <article-title>Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-66</page-range>
            <pub-id pub-id-type="pmid">22484399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Havrilesky</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kulasingam</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Terplan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cline</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>McCrory</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Management of adnexal mass.</article-title>
            <source>Evid Rep Technol Assess (Full Rep)</source>
            <year>2006</year>
            <month>Feb</month>
            <issue>130</issue>
            <fpage>1</fpage>
            <page-range>1-145</page-range>
            <pub-id pub-id-type="pmid">17854238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Funston</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crosbie</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rous</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.</article-title>
            <source>PLoS Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>e1003295</fpage>
            <pub-id pub-id-type="pmid">33112854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prat</surname>
                <given-names>J</given-names>
              </name>
              <collab>FIGO Committee on Gynecologic Oncology</collab>
            </person-group>
            <article-title>Staging classification for cancer of the ovary, fallopian tube, and peritoneum.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">24219974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians anf Gynecologists</collab>
            <article-title>ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.</article-title>
            <source>Obstet Gynecol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>100</volume>
            <issue>6</issue>
            <fpage>1413</fpage>
            <page-range>1413-6</page-range>
            <pub-id pub-id-type="pmid">12468197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buys</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Partridge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lamerato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reding</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Yokochi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kessel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Weissfeld</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fouad</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ragard</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Clapp</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rathmell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Izmirlian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Prorok</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Gohagan</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>CD</given-names>
              </name>
              <collab>PLCO Project Team</collab>
            </person-group>
            <article-title>Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.</article-title>
            <source>JAMA</source>
            <year>2011</year>
            <month>Jun</month>
            <day>08</day>
            <volume>305</volume>
            <issue>22</issue>
            <fpage>2295</fpage>
            <page-range>2295-303</page-range>
            <pub-id pub-id-type="pmid">21642681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rustin</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Can we now agree to use the same definition to measure response according to CA-125?</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Oct</month>
            <day>15</day>
            <volume>22</volume>
            <issue>20</issue>
            <fpage>4035</fpage>
            <page-range>4035-6</page-range>
            <pub-id pub-id-type="pmid">15364965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rustin</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thigpen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pujade-Lauraine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jakobsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eisenhauer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sagae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greven</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vergote</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermorken</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2004</year>
            <month>Mar</month>
            <day>17</day>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-8</page-range>
            <pub-id pub-id-type="pmid">15026475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu Hassaan</surname>
                <given-names>SO</given-names>
              </name>
            </person-group>
            <article-title>Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.</article-title>
            <source>Dan Med J</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29619933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu Hassan</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tuxen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>S&#x000f6;l&#x000e9;tormos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation.</article-title>
            <source>Biomark Med</source>
            <year>2015</year>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>911</fpage>
            <page-range>911-22</page-range>
            <pub-id pub-id-type="pmid">26145714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sorosky</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buller</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.</article-title>
            <source>Obstet Gynecol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">12100804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Chay</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.</article-title>
            <source>Yonsei Med J</source>
            <year>2016</year>
            <month>May</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>580</fpage>
            <page-range>580-7</page-range>
            <pub-id pub-id-type="pmid">26996555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinns</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pitkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Housley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Internal quality control: best practice.</article-title>
            <source>J Clin Pathol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>1027</fpage>
            <page-range>1027-32</page-range>
            <pub-id pub-id-type="pmid">24072731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westgard</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Internal quality control: planning and implementation strategies.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>Pt 6</issue>
            <fpage>593</fpage>
            <page-range>593-611</page-range>
            <pub-id pub-id-type="pmid">14629798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoenmakers</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Naus</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>van Loon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Practical application of Sigma Metrics QC procedures in clinical chemistry.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>11</issue>
            <fpage>1837</fpage>
            <page-range>1837-43</page-range>
            <pub-id pub-id-type="pmid">21801029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orton</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Proficiency testing today.</article-title>
            <source>MLO Med Lab Obs</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>24</fpage>
            <page-range>24, 26</page-range>
            <pub-id pub-id-type="pmid">29924566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <collab>Joint Commission on Accreditation of Healthcare Organizations</collab>
            <article-title>Accepted: Revised laboratory proficiency testing requirement.</article-title>
            <source>Jt Comm Perspect</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>4</fpage>
            <pub-id pub-id-type="pmid">22312774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jagtap</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Badge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohale</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wankhade</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>The Role of the Biosafety Cabinet in Preventing Infection in the Clinical Laboratory.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e51309</fpage>
            <pub-id pub-id-type="pmid">38288229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vonesch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tomao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Renzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Signorini</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Biosafety in laboratories concerning exposure to biological agents].</article-title>
            <source>G Ital Med Lav Ergon</source>
            <year>2006</year>
            <season>Oct-Dec</season>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>444</fpage>
            <page-range>444-56</page-range>
            <pub-id pub-id-type="pmid">17380946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Siniyeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Shehri</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Safety in Medical Laboratories: Perception and Practice of University Students and Laboratory Workers.</article-title>
            <source>Appl Biosaf</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>Suppl 1</issue>
            <fpage>S34</fpage>
            <page-range>S34-S42</page-range>
            <pub-id pub-id-type="pmid">36032652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vernooij</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heintz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Witteveen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.</article-title>
            <source>Gynecol Oncol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>801</fpage>
            <page-range>801-12</page-range>
            <pub-id pub-id-type="pmid">17433422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganesan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hariprasad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dawar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vijayaraghavan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Improving care in ovarian cancer: the role of a clinico-pathological meeting.</article-title>
            <source>Natl Med J India</source>
            <year>2008</year>
            <season>Sep-Oct</season>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-7</page-range>
            <pub-id pub-id-type="pmid">19320321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Managing women with ovarian cancer: the role of the nurse.</article-title>
            <source>Nurs Stand</source>
            <year>2010</year>
            <month>Oct</month>
            <day>6-12</day>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>41</fpage>
            <page-range>41-9; quiz 50</page-range>
            <pub-id pub-id-type="pmid">21133017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-101263.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junor</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hole</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Management of ovarian cancer: referral to a multidisciplinary team matters.</article-title>
            <source>Br J Cancer</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>363</fpage>
            <page-range>363-70</page-range>
            <pub-id pub-id-type="pmid">8054286</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
